Contact
searchSearch
HMP Global
Login

Diffuse Large B-Cell Lymphoma Specialty Channel

Diffuse Large B-Cell Lymphoma
Specialty Channel
News
R-CHOP-Like Therapy Retreatment Yields Durable Responses in Late-Relapsing Diffuse Large B-Cell Lymphoma
04/17/2026
Emily Estrada
In older patients with late-relapsing DLBCL, R-CHOP-like therapy retreatment produced meaningful response rates and survival outcomes, though many patients required less intensive therapies at relapse and outcomes remained influenced by...
In older patients with late-relapsing DLBCL, R-CHOP-like therapy retreatment produced meaningful response rates and survival outcomes, though many patients required less intensive therapies at relapse and outcomes remained influenced by...
In older patients with...
04/17/2026
Oncology
News
Axicabtagene Ciloleucel Plus Atezolizumab Demonstrates Promise in Relapsed/Refractory Large B-Cell Lymphoma
01/28/2026
Stephanie Holland
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2...
01/28/2026
Oncology
Chan Cheah, MBBS
Conference Coverage
Epcoritamab Plus R-Mini-CHOP Demonstrates Durable Efficacy and Manageable Safety for Elderly Patients With DLBCL: 2-Year Results From EPCORE NHL-2
12/23/2025
Chan Cheah, MBBS
Epcoritamab plus R-mini-CHOP achieved high and durable response rates with manageable toxicity among elderly, treatment-naïve patients with DLBCL, according to results presented at the 2025 ASH Annual Meeting & Exposition.
Epcoritamab plus R-mini-CHOP achieved high and durable response rates with manageable toxicity among elderly, treatment-naïve patients with DLBCL, according to results presented at the 2025 ASH Annual Meeting & Exposition.
Epcoritamab plus R-mini-CHOP...
12/23/2025
Oncology
Krish Patel, MD
Conference Coverage
Quality Improvement Project Identifies Knowledge Gaps and Barriers to Bispecific Antibody Use in Community Oncology Practices
12/17/2025
Krish Patel, MD
At the 2025 ASH Annual Meeting & Exposition, Krish Patel, MD, shared insights into the development of a quality improvement initiative aimed to identify barriers of bispecific antibody use in community oncology practices.
At the 2025 ASH Annual Meeting & Exposition, Krish Patel, MD, shared insights into the development of a quality improvement initiative aimed to identify barriers of bispecific antibody use in community oncology practices.
At the 2025 ASH Annual Meeting &...
12/17/2025
Oncology
Conference Coverage
Real-World ctDNA Monitoring Shows MRD Clearance Predicts Relapse Risk and Survival Outcomes for DLBCL: HOVON-902 Analysis
12/11/2025
Emily Estrada
Serial ctDNA MRD monitoring among patients with DLBCL may predict relapse risk and survival outcomes, according to real-world study results presented at the 2025 ASH Annual Meeting & Exposition.
Serial ctDNA MRD monitoring among patients with DLBCL may predict relapse risk and survival outcomes, according to real-world study results presented at the 2025 ASH Annual Meeting & Exposition.
Serial ctDNA MRD monitoring...
12/11/2025
Oncology
Conference Coverage
Odronextamab Plus CHOP Demonstrates High Response Rates and Manageable Safety for Previously Untreated DLBCL: First Results From OLYMPIA-3 Trial
12/03/2025
Emily Estrada
Odronextamab plus CHOP chemotherapy achieved high response rates and manageable toxicity for previously untreated DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Odronextamab plus CHOP chemotherapy achieved high response rates and manageable toxicity for previously untreated DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Odronextamab plus CHOP...
12/03/2025
Oncology
Conference Coverage
Epcoritamab Monotherapy Demonstrates High Response Rates and Durable MRD Negativity in Elderly, Chemotherapy-Ineligible 1L DLBCL Patients: Interim Results from EPCORE DLBCL-3
12/03/2025
Emily Estrada
Fixed-duration subcutaneous epcoritamab monotherapy demonstrated promising efficacy, early and sustained MRD negativity, and manageable safety among patients with DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Fixed-duration subcutaneous epcoritamab monotherapy demonstrated promising efficacy, early and sustained MRD negativity, and manageable safety among patients with DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Fixed-duration subcutaneous...
12/03/2025
Oncology
Conference Coverage
Zanubrutinib Plus R-CHOP Therapy Shows Promising Efficacy, Acceptable Safety Among Patients With DLBCL Harboring Specific Gene Subtypes
12/02/2025
Emily Estrada
Zanubrutinib and R-CHOP therapy demonstrated encouraging anti-tumor activity and acceptable tolerability among patients with diffuse large B-cell lymphoma with certain genetic alterations, according to data presented at the 2025 ASH Annual...
Zanubrutinib and R-CHOP therapy demonstrated encouraging anti-tumor activity and acceptable tolerability among patients with diffuse large B-cell lymphoma with certain genetic alterations, according to data presented at the 2025 ASH Annual...
Zanubrutinib and R-CHOP therapy...
12/02/2025
Oncology
Conference Coverage
Subcutaneous Mosunetuzumab Shows Efficacy and Safety Among Elderly, Chemotherapy-Ineligible Patients With DLBCL: MorningSun Trial
12/02/2025
Emily Estrada
According to data presented at the 2025 ASH Annual Meeting, fixed-duration subcutaneous mosunetuzumab monotherapy achieved high response rates with manageable toxicity among elderly/unfit patients with diffuse large B-cell lymphoma.
According to data presented at the 2025 ASH Annual Meeting, fixed-duration subcutaneous mosunetuzumab monotherapy achieved high response rates with manageable toxicity among elderly/unfit patients with diffuse large B-cell lymphoma.
According to data presented at...
12/02/2025
Oncology
Quiz
Polatuzumab-Based Therapy for R/R DLBCL
12/01/2025
True or False: Polatuzumab vedotin combined with rituximab and bendamustine demonstrated inferior overall survival compared with conventional chemotherapy among patients with R/R diffuse large B-cell lymphoma.
True or False: Polatuzumab vedotin combined with rituximab and bendamustine demonstrated inferior overall survival compared with conventional chemotherapy among patients with R/R diffuse large B-cell lymphoma.
True or False: Polatuzumab...
12/01/2025
Oncology
News
Nivolumab Plus R-CHOP Shows Promising Efficacy and Tolerability for Newly Diagnosed DLBCL
12/01/2025
Emily Estrada
According to results from a phase 1b study, the addition of nivolumab to standard R-CHOP therapy demonstrated promising response rates and a manageable safety profile for patients with newly diagnosed aggressive diffuse large B-cell lymphoma.
According to results from a phase 1b study, the addition of nivolumab to standard R-CHOP therapy demonstrated promising response rates and a manageable safety profile for patients with newly diagnosed aggressive diffuse large B-cell lymphoma.
According to results from a...
12/01/2025
Oncology

News

News
R-CHOP-Like Therapy Retreatment Yields Durable Responses in Late-Relapsing Diffuse Large B-Cell Lymphoma
04/17/2026
Emily Estrada
In older patients with late-relapsing DLBCL, R-CHOP-like therapy retreatment produced meaningful response rates and survival outcomes, though many patients required less intensive therapies at relapse and outcomes remained influenced by...
In older patients with late-relapsing DLBCL, R-CHOP-like therapy retreatment produced meaningful response rates and survival outcomes, though many patients required less intensive therapies at relapse and outcomes remained influenced by...
In older patients with...
04/17/2026
Oncology
News
Axicabtagene Ciloleucel Plus Atezolizumab Demonstrates Promise in Relapsed/Refractory Large B-Cell Lymphoma
01/28/2026
Stephanie Holland
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2...
01/28/2026
Oncology
Conference Coverage
Real-World ctDNA Monitoring Shows MRD Clearance Predicts Relapse Risk and Survival Outcomes for DLBCL: HOVON-902 Analysis
12/11/2025
Emily Estrada
Serial ctDNA MRD monitoring among patients with DLBCL may predict relapse risk and survival outcomes, according to real-world study results presented at the 2025 ASH Annual Meeting & Exposition.
Serial ctDNA MRD monitoring among patients with DLBCL may predict relapse risk and survival outcomes, according to real-world study results presented at the 2025 ASH Annual Meeting & Exposition.
Serial ctDNA MRD monitoring...
12/11/2025
Oncology
Conference Coverage
Odronextamab Plus CHOP Demonstrates High Response Rates and Manageable Safety for Previously Untreated DLBCL: First Results From OLYMPIA-3 Trial
12/03/2025
Emily Estrada
Odronextamab plus CHOP chemotherapy achieved high response rates and manageable toxicity for previously untreated DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Odronextamab plus CHOP chemotherapy achieved high response rates and manageable toxicity for previously untreated DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Odronextamab plus CHOP...
12/03/2025
Oncology
Conference Coverage
Epcoritamab Monotherapy Demonstrates High Response Rates and Durable MRD Negativity in Elderly, Chemotherapy-Ineligible 1L DLBCL Patients: Interim Results from EPCORE DLBCL-3
12/03/2025
Emily Estrada
Fixed-duration subcutaneous epcoritamab monotherapy demonstrated promising efficacy, early and sustained MRD negativity, and manageable safety among patients with DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Fixed-duration subcutaneous epcoritamab monotherapy demonstrated promising efficacy, early and sustained MRD negativity, and manageable safety among patients with DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Fixed-duration subcutaneous...
12/03/2025
Oncology
Conference Coverage
Zanubrutinib Plus R-CHOP Therapy Shows Promising Efficacy, Acceptable Safety Among Patients With DLBCL Harboring Specific Gene Subtypes
12/02/2025
Emily Estrada
Zanubrutinib and R-CHOP therapy demonstrated encouraging anti-tumor activity and acceptable tolerability among patients with diffuse large B-cell lymphoma with certain genetic alterations, according to data presented at the 2025 ASH Annual...
Zanubrutinib and R-CHOP therapy demonstrated encouraging anti-tumor activity and acceptable tolerability among patients with diffuse large B-cell lymphoma with certain genetic alterations, according to data presented at the 2025 ASH Annual...
Zanubrutinib and R-CHOP therapy...
12/02/2025
Oncology
Conference Coverage
Subcutaneous Mosunetuzumab Shows Efficacy and Safety Among Elderly, Chemotherapy-Ineligible Patients With DLBCL: MorningSun Trial
12/02/2025
Emily Estrada
According to data presented at the 2025 ASH Annual Meeting, fixed-duration subcutaneous mosunetuzumab monotherapy achieved high response rates with manageable toxicity among elderly/unfit patients with diffuse large B-cell lymphoma.
According to data presented at the 2025 ASH Annual Meeting, fixed-duration subcutaneous mosunetuzumab monotherapy achieved high response rates with manageable toxicity among elderly/unfit patients with diffuse large B-cell lymphoma.
According to data presented at...
12/02/2025
Oncology
News
Nivolumab Plus R-CHOP Shows Promising Efficacy and Tolerability for Newly Diagnosed DLBCL
12/01/2025
Emily Estrada
According to results from a phase 1b study, the addition of nivolumab to standard R-CHOP therapy demonstrated promising response rates and a manageable safety profile for patients with newly diagnosed aggressive diffuse large B-cell lymphoma.
According to results from a phase 1b study, the addition of nivolumab to standard R-CHOP therapy demonstrated promising response rates and a manageable safety profile for patients with newly diagnosed aggressive diffuse large B-cell lymphoma.
According to results from a...
12/01/2025
Oncology
News
Rituximab and Lenalidomide Plus Ibrutinib Therapy Shows Promising Activity, Manageable Toxicity in Real-World Setting for Relapsed/Refractory DLBCL
12/01/2025
Emily Estrada
The combination of rituximab, lenalidomide, and ibrutinib demonstrated promising efficacy and survival outcomes for patients with relapsed/refractory diffuse large B-cell lymphoma in a retrospective real-world analysis.
The combination of rituximab, lenalidomide, and ibrutinib demonstrated promising efficacy and survival outcomes for patients with relapsed/refractory diffuse large B-cell lymphoma in a retrospective real-world analysis.
The combination of rituximab,...
12/01/2025
Oncology
News
Ibrutinib-Based Triple Therapy Yields Durable Responses for Newly Diagnosed Primary CNS DLBCL
10/28/2025
Emily Estrada
For patients with newly diagnosed primary central nervous system diffuse large B-cell lymphoma, first-line treatment with ibrutinib, rituximab, and high-dose methotrexate demonstrated promising outcomes and manageable safety.
For patients with newly diagnosed primary central nervous system diffuse large B-cell lymphoma, first-line treatment with ibrutinib, rituximab, and high-dose methotrexate demonstrated promising outcomes and manageable safety.
For patients with newly...
10/28/2025
Oncology
News
Enfortumab Vedotin Plus Pembrolizumab Maintains Long-Term Survival Benefit in Advanced Urothelial Carcinoma
06/01/2026
Emily Estrada
Results from the EV-302/KEYNOTE-A39 trial demonstrated that enfortumab vedotin plus pembrolizumab maintained a durable survival benefit in previously untreated patients with locally advanced or metastatic urothelial carcinoma.
Results from the EV-302/KEYNOTE-A39 trial demonstrated that enfortumab vedotin plus pembrolizumab maintained a durable survival benefit in previously untreated patients with locally advanced or metastatic urothelial carcinoma.
Results from the...
06/01/2026
Oncology
News
Ropeginterferon Shows Efficacy Across Treatment Lines and Mutation Subtypes in Essential Thrombocythemia
06/01/2026
Stephanie Holland
Results from an integrated analysis of the SURPASS-ET and EXCEED-ET studies demonstrated consistent hematologic and molecular efficacy with ropeginterferon alfa-2b across diverse patient populations with essential thrombocythemia.
Results from an integrated analysis of the SURPASS-ET and EXCEED-ET studies demonstrated consistent hematologic and molecular efficacy with ropeginterferon alfa-2b across diverse patient populations with essential thrombocythemia.
Results from an integrated...
06/01/2026
Oncology
News
Asandeutertinib Demonstrates Superior Intracranial Efficacy in EGFR-Mutated NSCLC
05/31/2026
Emily Estrada
Results from the ESAONA asandeutertinib significantly improved intracranial response rates and intracranial progression-free survival in patients with EGFR-mutated NSCLC and brain metastases.
Results from the ESAONA asandeutertinib significantly improved intracranial response rates and intracranial progression-free survival in patients with EGFR-mutated NSCLC and brain metastases.
Results from the ESAONA...
05/31/2026
Oncology
News
BREAKWATER Expands First-Line Treatment Options for Patients With BRAF V600E–Mutant Metastatic Colorectal Cancer
05/31/2026
Stephanie Holland
First-line encorafenib, cetuximab, and FOLFIRI significantly improved response rates and PFS and prolonged OS vs FOLFIRI ± bevacizumab in patients with BRAF V600E–mutant metastatic colorectal cancer, according to findings from cohort 3 of the...
First-line encorafenib, cetuximab, and FOLFIRI significantly improved response rates and PFS and prolonged OS vs FOLFIRI ± bevacizumab in patients with BRAF V600E–mutant metastatic colorectal cancer, according to findings from cohort 3 of the...
First-line encorafenib,...
05/31/2026
Oncology
News
HARMONi-6 Trial Positions Ivonescimab Plus Chemotherapy as New First-Line Standard of Care in Squamous NSCLC
05/31/2026
Emily Estrada
Results from the HARMONi-6 trial position ivonescimab plus chemotherapy as a new first-line standard-of-care for patients with squamous non-small cell lung cancer.
Results from the HARMONi-6 trial position ivonescimab plus chemotherapy as a new first-line standard-of-care for patients with squamous non-small cell lung cancer.
Results from the HARMONi-6 trial...
05/31/2026
Oncology
News
Metronomic Chemo-Immunotherapy Improves Survival in Metastatic Head and Neck Cancer
05/31/2026
Stephanie Holland
Results from a phase 3 trial showed that triple oral metronomic chemotherapy combined with ultra-low-dose nivolumab demonstrates clinical promise among patients with recurrent or metastatic head and neck squamous cell carcinoma.
Results from a phase 3 trial showed that triple oral metronomic chemotherapy combined with ultra-low-dose nivolumab demonstrates clinical promise among patients with recurrent or metastatic head and neck squamous cell carcinoma.
Results from a phase 3 trial...
05/31/2026
Oncology
News
Adding Sintilimab to Adjuvant Capecitabine Fails to Improve PFS in High-Risk Nasopharyngeal Carcinoma
05/31/2026
Stephanie Holland
Results from a randomized phase 2 trial demonstrated that adding sintilimab to adjuvant capecitabine did not significantly improve PFS in patients with locoregionally advanced nasopharyngeal carcinoma who experienced a suboptimal response to...
Results from a randomized phase 2 trial demonstrated that adding sintilimab to adjuvant capecitabine did not significantly improve PFS in patients with locoregionally advanced nasopharyngeal carcinoma who experienced a suboptimal response to...
Results from a randomized phase...
05/31/2026
Oncology
News
Talazoparib Plus Enzalutamide Reduces Risk of Radiographic Progression in HRR-Deficient Metastatic Castration-Sensitive Prostate Cancer
05/30/2026
Stephanie Holland
Results from the phase 3 TALAPRO-3 trial demonstrated that talazoparib plus enzalutamide significantly improved radiographic progression-free survival in HRR-deficient metastatic castration-sensitive prostate cancer.
Results from the phase 3 TALAPRO-3 trial demonstrated that talazoparib plus enzalutamide significantly improved radiographic progression-free survival in HRR-deficient metastatic castration-sensitive prostate cancer.
Results from the phase 3...
05/30/2026
Oncology
News
Omitting Axillary Lymph Node Dissection Appears Safe in Node-Positive Breast Cancer
05/30/2026
Stephanie Holland
Results from the phase 3 SENOMAC trial demonstrated that omitting axillary lymph node dissection following a positive sentinel lymph node biopsy appears safe in patients with early-stage breast cancer.
Results from the phase 3 SENOMAC trial demonstrated that omitting axillary lymph node dissection following a positive sentinel lymph node biopsy appears safe in patients with early-stage breast cancer.
Results from the phase 3 SENOMAC...
05/30/2026
Oncology
News
Anbenitamab Demonstrates Significant Neoadjuvant Benefit in HER2-Positive Breast Cancer
05/30/2026
Stephanie Holland
Results from a phase 3 trial demonstrated that anbenitamab plus chemotherapy significantly improved total pCR compared with standard neoadjuvant HER2-directed therapy in HER2-positive early or locally advanced breast cancer.
Results from a phase 3 trial demonstrated that anbenitamab plus chemotherapy significantly improved total pCR compared with standard neoadjuvant HER2-directed therapy in HER2-positive early or locally advanced breast cancer.
Results from a phase 3 trial...
05/30/2026
Oncology

Interactive Features

Quiz
Polatuzumab-Based Therapy for R/R DLBCL
12/01/2025
True or False: Polatuzumab vedotin combined with rituximab and bendamustine demonstrated inferior overall survival compared with conventional chemotherapy among patients with R/R diffuse large B-cell lymphoma.
True or False: Polatuzumab vedotin combined with rituximab and bendamustine demonstrated inferior overall survival compared with conventional chemotherapy among patients with R/R diffuse large B-cell lymphoma.
True or False: Polatuzumab...
12/01/2025
Oncology
Quiz
Polatuzumab-Based Regimens for R/R DLBCL
10/28/2025
True or False: Compared to patients with R/R DLBCL treated with traditional salvage therapies, patients treated with polatuzumab vedotin and zanubrutinib combined with either rituximab or obinutuzumab demonstrated inferior clinical outcomes...
True or False: Compared to patients with R/R DLBCL treated with traditional salvage therapies, patients treated with polatuzumab vedotin and zanubrutinib combined with either rituximab or obinutuzumab demonstrated inferior clinical outcomes...
True or False: Compared to...
10/28/2025
Oncology
Quiz
Epcoritamab Plus R-ICE for R/R DLBCL
09/26/2025
True or False: According to results from the EPCORE NHL-2 clinical trial, the addition of epcoritamab to standard R-ICE therapy demonstrated high overall and complete response rates among patients with R/R DLBCL eligible for autologous stem...
True or False: According to results from the EPCORE NHL-2 clinical trial, the addition of epcoritamab to standard R-ICE therapy demonstrated high overall and complete response rates among patients with R/R DLBCL eligible for autologous stem...
True or False: According to...
09/26/2025
Oncology
Quiz
Efficacy and Safety of Tazemetostat for R/R DLBCL and FL
08/25/2025
True or False: Based on results from a meta-analysis evaluating the safety and efficacy of tazemetostat among patients with R/R FL or DLBCL, the EZH2 inhibitor demonstrated promise as a viable treatment option, demonstrating meaningful...
True or False: Based on results from a meta-analysis evaluating the safety and efficacy of tazemetostat among patients with R/R FL or DLBCL, the EZH2 inhibitor demonstrated promise as a viable treatment option, demonstrating meaningful...
True or False: Based on results...
08/25/2025
Oncology
Quiz
Autologous Hematopoietic Cell Transplantation or CAR-T Therapy for Patients With Relapsed LBCL
09/30/2024
True or False: According to results from a retrospective observational study, among patients with relapsed large B-cell lymphoma who achieve a complete remission, treatment with autologous hematopoietic cell transplantation fails to...
True or False: According to results from a retrospective observational study, among patients with relapsed large B-cell lymphoma who achieve a complete remission, treatment with autologous hematopoietic cell transplantation fails to...
True or False: According to...
09/30/2024
Oncology
Quiz
Induction Therapy With High-Dose Chemo, Autologous HSCT in Patients With PCNSL
04/11/2024
04/11/2024
Oncology
Quiz
Blinatumomab After ASCT as a Treatment Option Among Patients With Relapsed DLBCL
02/27/2024
02/27/2024
Oncology
Quiz
Treating DLBCL With Tafasitamab Plus R-CHOP, With or Without Lenalidomide
12/15/2023
True or False: According to findings from the phase 1b First-MIND study, tafasitamab plus the rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) regimen with or without the addition of lenalidomide demonstrated...
True or False: According to findings from the phase 1b First-MIND study, tafasitamab plus the rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) regimen with or without the addition of lenalidomide demonstrated...
True or False: According to...
12/15/2023
Oncology
Quiz
Acalabrutinib Plus Danvatirsen for R/R DLBCL
12/05/2023
What were the key findings of the phase 1 PRISM trial, which investigated the use of BTK inhibitor acalabrutinib plus STAT3 inhibitor danvatirsen among patients with R/R DLBCL?
What were the key findings of the phase 1 PRISM trial, which investigated the use of BTK inhibitor acalabrutinib plus STAT3 inhibitor danvatirsen among patients with R/R DLBCL?
What were the key findings of...
12/05/2023
Oncology
Quiz
Standard vs 4-Cycle Regimen of R-CHOP for Non-Bulky, Low-Risk DLBCL
11/07/2023
According to findings from a phase 3 trial, how did a 4-cycle regimen of R-CHOP compare to the standard regimen in treating patients with non-bulky, low-risk DLBCL?
According to findings from a phase 3 trial, how did a 4-cycle regimen of R-CHOP compare to the standard regimen in treating patients with non-bulky, low-risk DLBCL?
According to findings from a...
11/07/2023
Oncology
White Blood Cell Count Control in Polycythemia Vera (PV) Management: A Quiz Journey
PV Management Question 4
05/21/2026
Lucia Masarova, MD
Test your understanding of the relationship between leukocytosis, symptom burden, and disease activity in polycythemia vera.
Test your understanding of the relationship between leukocytosis, symptom burden, and disease activity in polycythemia vera.
Test your understanding of the...
05/21/2026
Oncology
White Blood Cell Count Control in Polycythemia Vera (PV) Management: A Quiz Journey
PV Management Question 3
05/21/2026
Lucia Masarova, MD
Learn how persistent leukocytosis may inform assessment of disease control and management decisions in polycythemia vera.
Learn how persistent leukocytosis may inform assessment of disease control and management decisions in polycythemia vera.
Learn how persistent...
05/21/2026
Oncology
White Blood Cell Count Control in Polycythemia Vera (PV) Management: A Quiz Journey
PV Management Question 2
05/21/2026
Lucia Masarova, MD
Review evidence evaluating the association between elevated white blood cell count and thrombotic risk in polycythemia vera.
Review evidence evaluating the association between elevated white blood cell count and thrombotic risk in polycythemia vera.
Review evidence evaluating the...
05/21/2026
Oncology
White Blood Cell Count Control in Polycythemia Vera (PV) Management: A Quiz Journey
PV Management Question 1
05/21/2026
Lucia Masarova, MD
Test your knowledge of the clinical relevance of white blood cell count control in polycythemia vera management.
Test your knowledge of the clinical relevance of white blood cell count control in polycythemia vera management.
Test your knowledge of the...
05/21/2026
Oncology
Current First-Line Treatments and Low-Risk Treatment Guidelines in Polycythemia Vera (PV): A Quiz Journey
PV Guidelines Question 5
05/21/2026
Michael R. Grunwald, MD
Learn more about the safety profile of interferon therapy in low-risk polycythemia vera.
Learn more about the safety profile of interferon therapy in low-risk polycythemia vera.
Learn more about the safety...
05/21/2026
Oncology
Current First-Line Treatments and Low-Risk Treatment Guidelines in Polycythemia Vera (PV): A Quiz Journey
PV Guidelines Question 4
05/21/2026
Michael R. Grunwald, MD
Review clinical features that may support consideration of cytoreductive therapy in patients with low-risk polycythemia vera.
Review clinical features that may support consideration of cytoreductive therapy in patients with low-risk polycythemia vera.
Review clinical features that...
05/21/2026
Oncology
Current First-Line Treatments and Low-Risk Treatment Guidelines in Polycythemia Vera (PV): A Quiz Journey
PV Guidelines Question 3
05/21/2026
Michael R. Grunwald, MD
Test your understanding of first-line cytoreductive therapy options for patients with high-risk polycythemia vera.
Test your understanding of first-line cytoreductive therapy options for patients with high-risk polycythemia vera.
Test your understanding of...
05/21/2026
Oncology
Current First-Line Treatments and Low-Risk Treatment Guidelines in Polycythemia Vera (PV): A Quiz Journey
PV Guidelines Question 2
05/20/2026
Learn when cytoreductive therapy should be considered for patients with low-risk polycythemia vera despite treatment with phlebotomy and aspirin.
Learn when cytoreductive therapy should be considered for patients with low-risk polycythemia vera despite treatment with phlebotomy and aspirin.
Learn when cytoreductive therapy...
05/20/2026
Oncology
Current First-Line Treatments and Low-Risk Treatment Guidelines in Polycythemia Vera (PV): A Quiz Journey
PV Guidelines Question 1
05/20/2026
Michael R. Grunwald, MD
Test your knowledge of current first-line treatment strategies in polycythemia vera.
Test your knowledge of current first-line treatment strategies in polycythemia vera.
Test your knowledge of current...
05/20/2026
Oncology
Quiz
Molecular Predictors of Survival With Ruxolitinib Plus Venetoclax in R/R Acute Myeloid Leukemia
05/01/2026
Which genomic feature predicts poor survival with ruxolitinib plus venetoclax in patients with R/R acute myeloid leukemia?
Which genomic feature predicts poor survival with ruxolitinib plus venetoclax in patients with R/R acute myeloid leukemia?
Which genomic feature predicts...
05/01/2026
Oncology

Recent News

News
R-CHOP-Like Therapy Retreatment Yields Durable Responses in Late-Relapsing Diffuse Large B-Cell Lymphoma
04/17/2026
Emily Estrada
In older patients with late-relapsing DLBCL, R-CHOP-like therapy retreatment produced meaningful response rates and survival outcomes, though many patients required less intensive therapies at relapse and outcomes remained influenced by...
In older patients with late-relapsing DLBCL, R-CHOP-like therapy retreatment produced meaningful response rates and survival outcomes, though many patients required less intensive therapies at relapse and outcomes remained influenced by...
In older patients with...
04/17/2026
Oncology
News
Axicabtagene Ciloleucel Plus Atezolizumab Demonstrates Promise in Relapsed/Refractory Large B-Cell Lymphoma
01/28/2026
Stephanie Holland
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2...
01/28/2026
Oncology
Conference Coverage
Real-World ctDNA Monitoring Shows MRD Clearance Predicts Relapse Risk and Survival Outcomes for DLBCL: HOVON-902 Analysis
12/11/2025
Emily Estrada
Serial ctDNA MRD monitoring among patients with DLBCL may predict relapse risk and survival outcomes, according to real-world study results presented at the 2025 ASH Annual Meeting & Exposition.
Serial ctDNA MRD monitoring among patients with DLBCL may predict relapse risk and survival outcomes, according to real-world study results presented at the 2025 ASH Annual Meeting & Exposition.
Serial ctDNA MRD monitoring...
12/11/2025
Oncology
Conference Coverage
Odronextamab Plus CHOP Demonstrates High Response Rates and Manageable Safety for Previously Untreated DLBCL: First Results From OLYMPIA-3 Trial
12/03/2025
Emily Estrada
Odronextamab plus CHOP chemotherapy achieved high response rates and manageable toxicity for previously untreated DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Odronextamab plus CHOP chemotherapy achieved high response rates and manageable toxicity for previously untreated DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Odronextamab plus CHOP...
12/03/2025
Oncology
Conference Coverage
Epcoritamab Monotherapy Demonstrates High Response Rates and Durable MRD Negativity in Elderly, Chemotherapy-Ineligible 1L DLBCL Patients: Interim Results from EPCORE DLBCL-3
12/03/2025
Emily Estrada
Fixed-duration subcutaneous epcoritamab monotherapy demonstrated promising efficacy, early and sustained MRD negativity, and manageable safety among patients with DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Fixed-duration subcutaneous epcoritamab monotherapy demonstrated promising efficacy, early and sustained MRD negativity, and manageable safety among patients with DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Fixed-duration subcutaneous...
12/03/2025
Oncology
Conference Coverage
Zanubrutinib Plus R-CHOP Therapy Shows Promising Efficacy, Acceptable Safety Among Patients With DLBCL Harboring Specific Gene Subtypes
12/02/2025
Emily Estrada
Zanubrutinib and R-CHOP therapy demonstrated encouraging anti-tumor activity and acceptable tolerability among patients with diffuse large B-cell lymphoma with certain genetic alterations, according to data presented at the 2025 ASH Annual...
Zanubrutinib and R-CHOP therapy demonstrated encouraging anti-tumor activity and acceptable tolerability among patients with diffuse large B-cell lymphoma with certain genetic alterations, according to data presented at the 2025 ASH Annual...
Zanubrutinib and R-CHOP therapy...
12/02/2025
Oncology
Conference Coverage
Subcutaneous Mosunetuzumab Shows Efficacy and Safety Among Elderly, Chemotherapy-Ineligible Patients With DLBCL: MorningSun Trial
12/02/2025
Emily Estrada
According to data presented at the 2025 ASH Annual Meeting, fixed-duration subcutaneous mosunetuzumab monotherapy achieved high response rates with manageable toxicity among elderly/unfit patients with diffuse large B-cell lymphoma.
According to data presented at the 2025 ASH Annual Meeting, fixed-duration subcutaneous mosunetuzumab monotherapy achieved high response rates with manageable toxicity among elderly/unfit patients with diffuse large B-cell lymphoma.
According to data presented at...
12/02/2025
Oncology
News
Nivolumab Plus R-CHOP Shows Promising Efficacy and Tolerability for Newly Diagnosed DLBCL
12/01/2025
Emily Estrada
According to results from a phase 1b study, the addition of nivolumab to standard R-CHOP therapy demonstrated promising response rates and a manageable safety profile for patients with newly diagnosed aggressive diffuse large B-cell lymphoma.
According to results from a phase 1b study, the addition of nivolumab to standard R-CHOP therapy demonstrated promising response rates and a manageable safety profile for patients with newly diagnosed aggressive diffuse large B-cell lymphoma.
According to results from a...
12/01/2025
Oncology
News
Rituximab and Lenalidomide Plus Ibrutinib Therapy Shows Promising Activity, Manageable Toxicity in Real-World Setting for Relapsed/Refractory DLBCL
12/01/2025
Emily Estrada
The combination of rituximab, lenalidomide, and ibrutinib demonstrated promising efficacy and survival outcomes for patients with relapsed/refractory diffuse large B-cell lymphoma in a retrospective real-world analysis.
The combination of rituximab, lenalidomide, and ibrutinib demonstrated promising efficacy and survival outcomes for patients with relapsed/refractory diffuse large B-cell lymphoma in a retrospective real-world analysis.
The combination of rituximab,...
12/01/2025
Oncology
News
Ibrutinib-Based Triple Therapy Yields Durable Responses for Newly Diagnosed Primary CNS DLBCL
10/28/2025
Emily Estrada
For patients with newly diagnosed primary central nervous system diffuse large B-cell lymphoma, first-line treatment with ibrutinib, rituximab, and high-dose methotrexate demonstrated promising outcomes and manageable safety.
For patients with newly diagnosed primary central nervous system diffuse large B-cell lymphoma, first-line treatment with ibrutinib, rituximab, and high-dose methotrexate demonstrated promising outcomes and manageable safety.
For patients with newly...
10/28/2025
Oncology
News
Enfortumab Vedotin Plus Pembrolizumab Maintains Long-Term Survival Benefit in Advanced Urothelial Carcinoma
06/01/2026
Emily Estrada
Results from the EV-302/KEYNOTE-A39 trial demonstrated that enfortumab vedotin plus pembrolizumab maintained a durable survival benefit in previously untreated patients with locally advanced or metastatic urothelial carcinoma.
Results from the EV-302/KEYNOTE-A39 trial demonstrated that enfortumab vedotin plus pembrolizumab maintained a durable survival benefit in previously untreated patients with locally advanced or metastatic urothelial carcinoma.
Results from the...
06/01/2026
Oncology
News
Ropeginterferon Shows Efficacy Across Treatment Lines and Mutation Subtypes in Essential Thrombocythemia
06/01/2026
Stephanie Holland
Results from an integrated analysis of the SURPASS-ET and EXCEED-ET studies demonstrated consistent hematologic and molecular efficacy with ropeginterferon alfa-2b across diverse patient populations with essential thrombocythemia.
Results from an integrated analysis of the SURPASS-ET and EXCEED-ET studies demonstrated consistent hematologic and molecular efficacy with ropeginterferon alfa-2b across diverse patient populations with essential thrombocythemia.
Results from an integrated...
06/01/2026
Oncology
News
Asandeutertinib Demonstrates Superior Intracranial Efficacy in EGFR-Mutated NSCLC
05/31/2026
Emily Estrada
Results from the ESAONA asandeutertinib significantly improved intracranial response rates and intracranial progression-free survival in patients with EGFR-mutated NSCLC and brain metastases.
Results from the ESAONA asandeutertinib significantly improved intracranial response rates and intracranial progression-free survival in patients with EGFR-mutated NSCLC and brain metastases.
Results from the ESAONA...
05/31/2026
Oncology
News
BREAKWATER Expands First-Line Treatment Options for Patients With BRAF V600E–Mutant Metastatic Colorectal Cancer
05/31/2026
Stephanie Holland
First-line encorafenib, cetuximab, and FOLFIRI significantly improved response rates and PFS and prolonged OS vs FOLFIRI ± bevacizumab in patients with BRAF V600E–mutant metastatic colorectal cancer, according to findings from cohort 3 of the...
First-line encorafenib, cetuximab, and FOLFIRI significantly improved response rates and PFS and prolonged OS vs FOLFIRI ± bevacizumab in patients with BRAF V600E–mutant metastatic colorectal cancer, according to findings from cohort 3 of the...
First-line encorafenib,...
05/31/2026
Oncology
News
HARMONi-6 Trial Positions Ivonescimab Plus Chemotherapy as New First-Line Standard of Care in Squamous NSCLC
05/31/2026
Emily Estrada
Results from the HARMONi-6 trial position ivonescimab plus chemotherapy as a new first-line standard-of-care for patients with squamous non-small cell lung cancer.
Results from the HARMONi-6 trial position ivonescimab plus chemotherapy as a new first-line standard-of-care for patients with squamous non-small cell lung cancer.
Results from the HARMONi-6 trial...
05/31/2026
Oncology
News
Metronomic Chemo-Immunotherapy Improves Survival in Metastatic Head and Neck Cancer
05/31/2026
Stephanie Holland
Results from a phase 3 trial showed that triple oral metronomic chemotherapy combined with ultra-low-dose nivolumab demonstrates clinical promise among patients with recurrent or metastatic head and neck squamous cell carcinoma.
Results from a phase 3 trial showed that triple oral metronomic chemotherapy combined with ultra-low-dose nivolumab demonstrates clinical promise among patients with recurrent or metastatic head and neck squamous cell carcinoma.
Results from a phase 3 trial...
05/31/2026
Oncology
News
Adding Sintilimab to Adjuvant Capecitabine Fails to Improve PFS in High-Risk Nasopharyngeal Carcinoma
05/31/2026
Stephanie Holland
Results from a randomized phase 2 trial demonstrated that adding sintilimab to adjuvant capecitabine did not significantly improve PFS in patients with locoregionally advanced nasopharyngeal carcinoma who experienced a suboptimal response to...
Results from a randomized phase 2 trial demonstrated that adding sintilimab to adjuvant capecitabine did not significantly improve PFS in patients with locoregionally advanced nasopharyngeal carcinoma who experienced a suboptimal response to...
Results from a randomized phase...
05/31/2026
Oncology
News
Talazoparib Plus Enzalutamide Reduces Risk of Radiographic Progression in HRR-Deficient Metastatic Castration-Sensitive Prostate Cancer
05/30/2026
Stephanie Holland
Results from the phase 3 TALAPRO-3 trial demonstrated that talazoparib plus enzalutamide significantly improved radiographic progression-free survival in HRR-deficient metastatic castration-sensitive prostate cancer.
Results from the phase 3 TALAPRO-3 trial demonstrated that talazoparib plus enzalutamide significantly improved radiographic progression-free survival in HRR-deficient metastatic castration-sensitive prostate cancer.
Results from the phase 3...
05/30/2026
Oncology
News
Omitting Axillary Lymph Node Dissection Appears Safe in Node-Positive Breast Cancer
05/30/2026
Stephanie Holland
Results from the phase 3 SENOMAC trial demonstrated that omitting axillary lymph node dissection following a positive sentinel lymph node biopsy appears safe in patients with early-stage breast cancer.
Results from the phase 3 SENOMAC trial demonstrated that omitting axillary lymph node dissection following a positive sentinel lymph node biopsy appears safe in patients with early-stage breast cancer.
Results from the phase 3 SENOMAC...
05/30/2026
Oncology
News
Anbenitamab Demonstrates Significant Neoadjuvant Benefit in HER2-Positive Breast Cancer
05/30/2026
Stephanie Holland
Results from a phase 3 trial demonstrated that anbenitamab plus chemotherapy significantly improved total pCR compared with standard neoadjuvant HER2-directed therapy in HER2-positive early or locally advanced breast cancer.
Results from a phase 3 trial demonstrated that anbenitamab plus chemotherapy significantly improved total pCR compared with standard neoadjuvant HER2-directed therapy in HER2-positive early or locally advanced breast cancer.
Results from a phase 3 trial...
05/30/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use